TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 871198

Group type: EXPERIMENTAL
Intervention: 4 ml 4% lignocaine spray
Number of subjects: 0

Group type: COMPARATOR
Intervention: 0-9% saline (control)
Number of subjects: 0
Study: 30267738

Group type: EXPERIMENTAL
Intervention: RNase1 treatment (pre-treated with RNase1 24 hours before A. hydrophila injection)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Control group (injected PBS)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Challenge group (A. hydrophila-injected)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Blank group (none-treated M. amblycephala)
Number of subjects: 4
Study: 28103255

Group type: EXPERIMENTAL
Intervention: Permethrin-impregnated school uniforms
Number of subjects: 1811

Group type: COMPARATOR
Intervention: Control schools (no intervention)
Number of subjects: 1811
Study: 25500425

Group type: EXPERIMENTAL
Intervention: Obeticholic acid (OCA) 10 mg, 25 mg, or 50 mg once daily for 3 months
Number of subjects: 165

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Obeticholic acid (OCA)
Number of subjects: 165
Study: 23876672

Group type: EXPERIMENTAL
Intervention: Prosocial behavior physical activity (PBPA) intervention, which includes structured physical activity sessions, cognitive-behavioral counseling, and opportunities to earn food for donation based on physical activity and volunteering.
Number of subjects: 300

Group type: COMPARATOR
Intervention: Healthy aging (HA) control intervention, based on educational sessions.
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Prosocial behavior physical activity (PBPA) intervention
Number of subjects: 300

Group type: COMPARATOR
Intervention: Healthy aging (HA) control intervention
Number of subjects: 300
Study: 21975193

Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT) plus treatment as usual (TAU)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Treatment as usual (TAU) alone
Number of subjects: 27
Study: 19291747

Group type: EXPERIMENTAL
Intervention: 1540 nm fractional laser treatments (three monthly treatments)
Number of subjects: 17

Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 17
Study: 16904063

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy package for generalized anxiety disorder (GAD)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Delayed treatment condition
Number of subjects: 18
Study: 15534640

Group type: EXPERIMENTAL
Intervention: Web-based communication system
Number of subjects: 200

Group type: COMPARATOR
Intervention: Traditional inquiries (visits, telephones)
Number of subjects: 200
Study: 15151713

Group type: EXPERIMENTAL
Intervention: Increased dose of human menopausal gonadotrophin (HMG) by 75 IU on the day of antagonist administration (Group B)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Standard dose of human menopausal gonadotrophin (HMG) (Group A)
Number of subjects: 151
Study: 10654498

Group type: EXPERIMENTAL
Intervention: Heparin‐coated circuit with silicone‐coated oxygenator (Group A)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Whole heparin‐coated circuit (Group B)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Whole untreated circuit (Group C)
Number of subjects: 32
Study: 9439154

Group type: EXPERIMENTAL
Intervention: 0.1N hydrochloric acid
Number of subjects: 12

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 12
Study: 8161673

Group type: EXPERIMENTAL
Intervention: PEG‐ELS 4 L plus simethicone 120 mg
Number of subjects: 115

Group type: COMPARATOR
Intervention: PEG‐ELS 4 L plus placebo
Number of subjects: 115
Study: 2868339

Group type: EXPERIMENTAL
Intervention: UKALL VIII treatment regimen including continuous therapy during induction, long course of intramuscular asparaginase over 3 weeks, full-dose mercaptopurine and co-trimoxazole during CNS prophylaxis, sustained maximum tolerated doses of mercaptopurine and methotrexate maintenance.
Number of subjects: 1470

Group type: EXPERIMENTAL
Intervention: UKALL VII treatment regimen for good-prognosis patients.
Number of subjects: 1470

Group type: COMPARATOR
Intervention: Previous UKALL trials (UKALL II to VI).
Number of subjects: 1470
Study: 2582828

Group type: EXPERIMENTAL
Intervention: MDI-spacer (0.36 mg of albuterol)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Nebulizer (2.5 mg of albuterol)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: MDI-spacer
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Nebulizer
Number of subjects: 20
Study: 30848846

Group type: EXPERIMENTAL
Intervention: Vaginal sacrospinous fixation (VSF)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Abdominal sacrocolpopexy (ASC)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Both VSF and ASC
Number of subjects: 71
Study: 27939230

Group type: EXPERIMENTAL
Intervention: Low-density lipoprotein cholesterol (LDL-C) variability
Number of subjects: 8658

Group type: EXPERIMENTAL
Intervention: Systolic blood pressure (BP) variability
Number of subjects: 8658

Group type: COMPARATOR
Intervention: High variability for both LDL-C and systolic BP
Number of subjects: 8658
Study: 25885341

Group type: EXPERIMENTAL
Intervention: Practice nurses (PNs) involvement in chlamydia testing
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Practice nurses (PNs) involvement in partner notification
Number of subjects: 44
Study: 23017611

Group type: EXPERIMENTAL
Intervention: Cardiopulmonary resuscitation (CPR)
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Mechanical ventilation (MV)
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Avoiding life-sustaining therapies
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Clinician error
Number of subjects: 196
Study: 21419769

Group type: EXPERIMENTAL
Intervention: Endoscopic trimodal imaging (ETMI)
Number of subjects: 234

Group type: COMPARATOR
Intervention: Standard video endoscopy (SVE)
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Narrow-band imaging (NBI)
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Autofluorescence imaging (AFI)
Number of subjects: 234
Study: 20137285

Group type: EXPERIMENTAL
Intervention: Serum IMA concentration in DR patients
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Serum hs-CRP concentration in DR patients
Number of subjects: 234

Group type: COMPARATOR
Intervention: Serum IMA concentration in NDR patients
Number of subjects: 234

Group type: COMPARATOR
Intervention: Serum hs-CRP concentration in NDR patients
Number of subjects: 234

Group type: COMPARATOR
Intervention: Serum IMA concentration in controls
Number of subjects: 234

Group type: COMPARATOR
Intervention: Serum hs-CRP concentration in controls
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Serum IMA concentration in PDR patients
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Serum hs-CRP concentration in PDR patients
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Serum IMA concentration in NPDR patients
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Serum hs-CRP concentration in NPDR patients
Number of subjects: 234
Study: 17366340

Group type: EXPERIMENTAL
Intervention: Self-selected posture for drivers
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Self-selected posture for front passengers
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Self-selected posture for rear passengers
Number of subjects: 154

Group type: COMPARATOR
Intervention: Sagging posture
Number of subjects: 154

Group type: COMPARATOR
Intervention: Age factor
Number of subjects: 154
Study: 14964743

Group type: EXPERIMENTAL
Intervention: Topical fluorouracil cream (0.5% 5-fluorouracil in a microsphere vehicle)
Number of subjects: 0
Study: 11434159

Group type: EXPERIMENTAL
Intervention: Automated Peritoneal Dialysis (APD)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Continuous Ambulatory Peritoneal Dialysis (CAPD)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: APD
Number of subjects: 52

Group type: COMPARATOR
Intervention: CAPD
Number of subjects: 52
Study: 9593407

Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy (surgery)
Number of subjects: 3024

Group type: COMPARATOR
Intervention: Control (surgery to be avoided for as long as possible)
Number of subjects: 3024
Study: 8017343

Group type: EXPERIMENTAL
Intervention: Vitamin B-6 supplementation
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo supplementation
Number of subjects: 20
Study: 2687008

Group type: EXPERIMENTAL
Intervention: Salbutamol controlled-release (SCR) 4 mg
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Salbutamol controlled-release (SCR) 8 mg
Number of subjects: 15
Study: 1103400

Group type: EXPERIMENTAL
Intervention: Daily regimen of streptomycin, isoniazid, and pyrazinamide
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: 3 times weekly regimen of streptomycin, isoniazid, and pyrazinamide
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: Twice weekly regimen of streptomycin, isoniazid, and pyrazinamide
Number of subjects: 211

Group type: COMPARATOR
Intervention: Overall relapse rates after 6 months' chemotherapy
Number of subjects: 211

Group type: COMPARATOR
Intervention: Overall relapse rates after 9 months' chemotherapy
Number of subjects: 211
Study: 31169772

Group type: EXPERIMENTAL
Intervention: Out-of-school older partners
Number of subjects: 1034

Group type: EXPERIMENTAL
Intervention: Anonymous out-of-school peer partners
Number of subjects: 1034

Group type: COMPARATOR
Intervention: Monogamous HIV-negative peer partners
Number of subjects: 1034

Group type: COMPARATOR
Intervention: Prespecified partner types
Number of subjects: 1034
Study: 28643323

Group type: EXPERIMENTAL
Intervention: Early intensified protocol of six cycles of CHOP-14 with dose-dense rituximab and high-dose methotrexate
Number of subjects: 63

Group type: COMPARATOR
Intervention: Four cycles R-CHOP-21 followed by first-line high-dose chemotherapy with autologous stem-cell support (HDCT-ASCT)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Cohort 2 (early intensified protocol) vs. Cohort 1 (R-CHOP-21)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Cohort 2 (early intensified protocol)
Number of subjects: 63
Study: 25758273

Group type: EXPERIMENTAL
Intervention: Rosuvastatin treatment
Number of subjects: 2998
Study: 23492914

Group type: EXPERIMENTAL
Intervention: Eltrombopag
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 20689320

Group type: EXPERIMENTAL
Intervention: Vitamin K₂ (menatetrenone) 45 mg/day for 1 year
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group without vitamin K₂
Number of subjects: 40
Study: 19938906

Group type: EXPERIMENTAL
Intervention: Seliciclib (CYC202, R-roscovitine)
Number of subjects: 0
Study: 17084786

Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI) style
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Confrontation
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Treatment condition, session sequence, and session date
Number of subjects: 46
Study: 15643481

Group type: EXPERIMENTAL
Intervention: Sodium hyaluronate (SH) injection (2 ml, Hyalgan, 20 mg/2 ml; once a week for 5 weeks)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Ringer's lactate solution (once a week for 3 weeks)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Sodium hyaluronate (SH) injection
Number of subjects: 27
Study: 11216739

Group type: EXPERIMENTAL
Intervention: CABG without CPB (n = 40)
Number of subjects: 80

Group type: COMPARATOR
Intervention: CABG with CPB (n = 40)
Number of subjects: 80
Study: 9807848

Group type: EXPERIMENTAL
Intervention: Laryngeal Mask Airway (LMA) insertion
Number of subjects: 48

Group type: COMPARATOR
Intervention: Endotracheal Tube (ETT) intubation
Number of subjects: 48
Study: 7799105

Group type: EXPERIMENTAL
Intervention: Nicardipine
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Calcium antagonists
Number of subjects: 31
Study: 2971582

Group type: EXPERIMENTAL
Intervention: 5% benzoyl peroxide/2% miconazole cream (BPO-MCZ)
Number of subjects: 52

Group type: COMPARATOR
Intervention: 5% benzoyl peroxide gel (BPO)
Number of subjects: 52
Study: 30664844

Group type: EXPERIMENTAL
Intervention: Ranibizumab every 4 weeks (Rq4)
Number of subjects: 747

Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept injection (IAI) 2 mg every 4 weeks (2q4)
Number of subjects: 747

Group type: EXPERIMENTAL
Intervention: IAI 2 mg every 8 weeks (2q8)
Number of subjects: 747

Group type: EXPERIMENTAL
Intervention: IAI 2 mg every 4 weeks (2q4)
Number of subjects: 747
Study: 25846350

Group type: EXPERIMENTAL
Intervention: Community Health Worker (CHW) intervention for 1 year
Number of subjects: 300

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 300
Study: 24373674

Group type: EXPERIMENTAL
Intervention: Ascope‐Trainer (group A)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Classic fiberscope (group C)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Both groups A and C
Number of subjects: 64

Group type: COMPARATOR
Intervention: Standard fiberscope (T1)
Number of subjects: 64
Study: 23208967

Group type: EXPERIMENTAL
Intervention: 50 mg dexketoprofen 30 minutes prior to the operation (group 50/0)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 50 mg dexketoprofen 30 minutes after the operation (group 0/50)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 25 mg dexketoprofen both 30 minutes prior and 30 minutes after the operation (group 25/25)
Number of subjects: 100

Group type: COMPARATOR
Intervention: No dexketoprofen (control group C)
Number of subjects: 100
Study: 19997572

Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure (CPAP) therapy for four weeks
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (16 controls without OSA)
Number of subjects: 16
Study: 17502332

Group type: COMPARATOR
Intervention: Passive Recovery (PR)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Active Cranking (AC)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Ventilatory Recovery (VR)
Number of subjects: 18
Study: 15310735

Group type: EXPERIMENTAL
Intervention: Cereal group (CR) consuming ready-to-eat cereal with low-fat milk 90 minutes after their evening meal for 4 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: No-cereal group (NC) continuing regular diet ad libitum
Number of subjects: 0
Study: 11532204

Group type: EXPERIMENTAL
Intervention: 6-hour course teaching computer use for evidence searching (1997-1998)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 5.5-hour course teaching SUMSearch use (1999-2000)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (students who did not receive the intervention)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Overall student satisfaction with search speed
Number of subjects: 0
Study: 9694028

Group type: EXPERIMENTAL
Intervention: D-fenfluramine (30 mg)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Methysergide (2 mg)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 7831873

Group type: EXPERIMENTAL
Intervention: Intracardiac laser light irradiation of blood
Number of subjects: 172
Study: 3071459

Group type: EXPERIMENTAL
Intervention: Ketanserin 10 to 30 mg twice daily
Number of subjects: 277

Group type: COMPARATOR
Intervention: Propranolol 20 to 40 mg 3 times daily
Number of subjects: 277
Study: 31050660

Group type: EXPERIMENTAL
Intervention: GR mirror therapy
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Conventional mirror therapy
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control
Number of subjects: 36
Study: 27600789

Group type: EXPERIMENTAL
Intervention: Mechanical debridement with adjunct antimicrobial photodynamic therapy (aPDT)
Number of subjects: 166

Group type: COMPARATOR
Intervention: Mechanical debridement alone
Number of subjects: 166
Study: 23999422

Group type: EXPERIMENTAL
Intervention: Hourly titrated oral misoprostol
Number of subjects: 160

Group type: COMPARATOR
Intervention: Dinoprostone 10 mg vaginal insert
Number of subjects: 160
Study: 22094327

Group type: EXPERIMENTAL
Intervention: EBRT dose of 70.2 Gy
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: EBRT dose of 79.2 Gy
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: PSA half life ratio
Number of subjects: 114
Study: 20097532

Group type: EXPERIMENTAL
Intervention: Hyperinsulinemic-normoglycemic clamp technique
Number of subjects: 110
Study: 18222415

Group type: EXPERIMENTAL
Intervention: Fear-relevant CSs with different contexts during extinction
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Fear-irrelevant CSs with different contexts during extinction
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Fear-relevant stimuli with indoor office context for acquisition and outdoor bush context for extinction
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Fear-irrelevant stimuli with outdoor bush context for acquisition and indoor office context for extinction
Number of subjects: 136
Study: 15922815

Group type: EXPERIMENTAL
Intervention: Oxycodone 5 mg/Ibuprofen 400 mg
Number of subjects: 249

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Oxycodone 5 mg/Acetaminophen 325 mg
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Hydrocodone 7.5 mg/Acetaminophen 500 mg
Number of subjects: 249
Study: 12533165

Group type: EXPERIMENTAL
Intervention: Botulinum toxin A (Dysport, 100 U dissolved in 0.9% sodium chloride solution)
Number of subjects: 16

Group type: COMPARATOR
Intervention: 0.9% sodium chloride solution (control)
Number of subjects: 16
Study: 10508209

Group type: EXPERIMENTAL
Intervention: Structured triacylglycerols containing predominantly stearic acid
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Structured triacylglycerols containing predominantly oleic acid
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Structured triacylglycerols (both types)
Number of subjects: 14
Study: 8646728

Group type: COMPARATOR
Intervention: Cisplatin (60 mg/m2 i.v.), Epirubicin (60 mg/m2 i.v.), Vindesine (3 mg/m2 i.v.)
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Cisplatin (60 mg/m2 i.v.), Epirubicin (60 mg/m2 i.v.), Vindesine (3 mg/m2 i.v.) + Lonidamine (75 mg orally three times on Day 1 to 150 mg orally three times on Day 7+)
Number of subjects: 158
Study: 8096416

Group type: EXPERIMENTAL
Intervention: salmeterol 200 micrograms
Number of subjects: 12

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: salmeterol 50 micrograms
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: salmeterol 100 micrograms
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: salmeterol (mean 6.4)
Number of subjects: 12
Study: 2950676

Group type: EXPERIMENTAL
Intervention: Thrombolysis plus immediate PTCA
Number of subjects: 411

Group type: COMPARATOR
Intervention: Thrombolysis alone
Number of subjects: 411

Group type: COMPARATOR
Intervention: Medical therapy
Number of subjects: 411

Group type: EXPERIMENTAL
Intervention: Immediate PTCA without prior thrombolysis
Number of subjects: 411
Study: 29714034

Group type: EXPERIMENTAL
Intervention: 800 mg oral CBD
Number of subjects: 30

Group type: COMPARATOR
Intervention: Matched placebo (PBO)
Number of subjects: 30
Study: 24825515

Group type: EXPERIMENTAL
Intervention: eGFR(CKD‐EPI‐Creat+CysC)
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: eGFR(MDRD)
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: eGFR(CKD‐EPI‐Creat)
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: eGFR(CKD‐EPI‐CysC)
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: CKD‐EPI models
Number of subjects: 257
Study: 22488276

Group type: EXPERIMENTAL
Intervention: Isotonic eccentric training (n = 11)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Isokinetic eccentric training (n = 10)
Number of subjects: 21
Study: 20107498

Group type: EXPERIMENTAL
Intervention: MSP1(42)-C1/Alhydrogel + CPG 7909
Number of subjects: 60

Group type: COMPARATOR
Intervention: MSP1(42)-C1/Alhydrogel
Number of subjects: 60
Study: 17882808

Group type: EXPERIMENTAL
Intervention: Mildronate (1 g/day) in addition to basic therapy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Basic therapy only
Number of subjects: 60
Study: 15635344

Group type: EXPERIMENTAL
Intervention: Plant sterols/stanols (2 g/day) incorporated into margarine (25 g/day)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Conventional management (Control group)
Number of subjects: 25
Study: 11850150

Group type: EXPERIMENTAL
Intervention: 0.5mg/kg metachlorophenylpiperazine (m‐CPP)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 10 mg ipsapirone
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 10049408

Group type: EXPERIMENTAL
Intervention: P‐EGD
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: T‐EGD
Number of subjects: 60
Study: 9183986

Group type: EXPERIMENTAL
Intervention: Distinctive feature judgments on upright faces
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Distinctive trait judgments on upright faces
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Distinctive expression judgments on upright faces
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Distinctive feature judgments on inverted faces
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Distinctive trait judgments on inverted faces
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Distinctive expression judgments on inverted faces
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Upright faces
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inverted faces
Number of subjects: 0
Study: 2700360

Group type: EXPERIMENTAL
Intervention: PT-01 treated site
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo treated site
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control site
Number of subjects: 0
Study: 1092514

Group type: EXPERIMENTAL
Intervention: Theophylline (7.3 mg/kg per dose administered every 6 hr)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Ephedrine (alone or in combination with theophylline and hydroxyzine)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Ephedrine-theophylline combinations (with and without hydroxyzine)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Theophylline alone
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Ephedrine-theophylline combinations
Number of subjects: 23
Study: 30773497

Group type: EXPERIMENTAL
Intervention: Tadalafil 5 mg daily
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group (group B)
Number of subjects: 38
Study: 29070048

Group type: EXPERIMENTAL
Intervention: Causal estimation methods
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intention-to-treat analysis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Per-protocol or as-treated analyses
Number of subjects: 0
Study: 25899697

Group type: EXPERIMENTAL
Intervention: Omalizumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0